A trial looking at durvalumab with or without tremelimumab for non small cell lung cancer that has spread (ARCTIC)

This trial compared durvalumab alone, or alongside tremelimumab, with usual treatment for people with non small cell lung cancer.

It was for people whose cancer had grown into surrounding tissues or had spread to another part of the body. This is locally advanced or advanced cancer.

This trial was open for people to join between 2015 and 2016. The team published the results in 2020.